Clinical studies have shown that inflammatory-related biomarkers are closely related to the non-response and prognosis of immunotherapy for HCC [133], including indicators such as the neutrophil-to-lymphocyte ratio (NLR) [134,135], platelet-to-lymphocyte ratio (PLR) [134], and C-reactive protein (CRP) [136]. This evidence concerns the gene CRP and hepatocellular carcinoma.